文献速递生殖医学

延长阴道孕酮补充时间不能改善供卵周期中第6天冻融囊胚移植的结局

Prolonged vaginal progesterone supplementation does not improve outcomes for Day 6 frozen blastocyst transfers in oocyte donation cycles.
PubMed 文献 · Hum Reprod · 2026-01-01

这项回顾性队列研究纳入2020年1月至2023年12月单中心420名供卵受者的485例冻融胚胎移植,比较阴道孕酮5天(P+5,n=282)与6天(P+6,n=203)对第6天囊胚移植结局的影响。结果显示两组生化妊娠率、临床妊娠率、持续妊娠率、活产率和流产率均无显著差异,延长孕酮补充时间未改善妊娠结局。

要点

  • 供卵周期第6天冻融囊胚移植中,阴道孕酮5天与6天的妊娠结局无显著差异。
  • 第6天囊胚移植结局较差可能反映胚胎自身发育迟缓,而非种植窗偏移。
  • 延长孕酮暴露未改善结局,提示种植窗可能比既往认为的更宽。

核心结论

  • 在供卵周期第6天冻融囊胚移植中,将阴道孕酮补充时间从5天延长至6天不能改善妊娠结局。

研究设计与样本

  • 回顾性队列研究,纳入2020年1月至2023年12月单中心420名供卵受者的485例冻融胚胎移植。
  • 按孕酮补充时间分为5天组(P+5,n=282)和6天组(P+6,n=203)。
  • 所有周期均行单枚第6天囊胚移植,子宫内膜准备采用阴道孕酮800 mg/天。
  • 采用单因素和多因素分析,逻辑回归校正雌激素类型和子宫内膜厚度。

主要发现

  • 受者平均年龄43.5(±4.24)岁,平均BMI 25.1,移植日平均子宫内膜厚度9.6 mm,优质囊胚占全部移植的35%。
  • 生化妊娠率P+5组26.24% vs P+6组26.60%(P=1.00),临床妊娠率21.99% vs 20.69%(P=0.83),持续妊娠率14.54% vs 13.30%(P=0.79)。
  • 活产率P+5组14.18% vs P+6组10.66%(P=0.27),流产率7.45% vs 7.39%(P=1.00),两组均无显著差异。
  • 校正分析确认上述结果。

临床怎么用

  • 作者认为,第6天冻融囊胚移植结局较差可能反映慢发育胚胎的内在限制,而非种植窗错位。
  • 作者认为,延长孕酮暴露未改善结局,种植窗可能比既往假设的更宽,尤其在供卵项目中优质胚胎可能抵消同步化偏差。

局限性

  • 回顾性设计需谨慎解读。
  • 结果仅适用于供卵周期中的阴道孕酮,可能不适用于其他人群或孕酮给药方式。
  • 分析的D6胚胎为第5天未达到囊胚者(发育延迟、预后差、通常最后移植),可能使活产率偏低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does extending vaginal progesterone administration from 5-6 days improve pregnancy outcomes in Day 6 (D6) frozen embryo transfers (FETs) in oocyte donation cycles? SUMMARY ANSWER: Prolonging the time of vaginal progesterone supplementation does not improve pregnancy outcomes after D6 FETs in oocyte recipients. WHAT IS KNOWN ALREADY: Progesterone is critical for endometrial preparation prior to embryo transfer, but the optimal duration of administration remains unclear. D6 blastocysts are associated with poorer clinical outcomes compared to Day 5 (D5) blastocysts, potentially due to either intrinsic limitations in implantation capacity or a shifted window of implantation (WOI). Extending progesterone administration has been hypothesized to optimize the WOI for D6 blastocysts. STUDY DESIGN, SIZE, DURATION: This retrospective cohort study included 485 FETs performed in 420 oocyte donation recipients, conducted from January 2020 to December 2023 in a single IVF center. Participants were divided into two groups based on the duration of progesterone supplementation: 5 days (P + 5, n = 282) and 6 days (P + 6, n = 203). PARTICIPANTS/MATERIALS, SETTING, METHODS: The study involved oocyte recipients undergoing single D6 blastocyst transfer following endometrial preparation with vaginal progesterone (800 mg/day). Outcomes were analyzed using univariate and multivariate tests, including logistic regression adjusted for estrogen type and endometrial thickness. MAIN RESULTS AND THE ROLE OF CHANCE: Mean recipient age (±SD) was 43.5 (±4.24) years, mean BMI was 25.1, and mean endometrial thickness was 9.6 mm on the day of transfer. Good-quality blastocysts accounted for 35% of all transfers. Clinical outcomes, including biochemical (26.24% vs 26.60%, P = 1.00), clinical (21.99% vs 20.69%, P = 0.83), and ongoing pregnancy (14.54% vs 13.30%, P = 0.79), as well as live birth (14.18% vs 10.66%, P = 0.27) and miscarriage rates (7.45% vs 7.39%, P = 1.00), were all similar between 5 and 6 days of progesterone supplementation, respectively. Adjusted analyses confirmed these findings. LIMITATIONS, REASONS FOR CAUTION: The retrospective design warrants careful interpretation. Results are specific to vaginal progesterone in oocyte donation cycles and may not apply to other populations or progesterone delivery methods. Additionally, the D6 embryos analyzed were those that did not reach blastocyst by Day 5 (delayed, poor-prognosis, and typically transferred last), which likely biases outcomes toward lower live birth rates. WIDER IMPLICATIONS OF THE FINDINGS: Compromised outcomes following D6 FETs compared to those of D5 blastocysts, likely reflect the intrinsic limitations of slow-developing embryos rather than a misaligned WOI. As prolonged progesterone exposure did not improve outcomes, the WOI may be broader than previously assumed, particularly in oocyte donation programs, where superior embryo quality may mitigate synchronization drawbacks. STUDY FUNDING/COMPETING INTEREST(S): This study was internally funded by the Eugin Clinic, with no external sponsorship. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: NA.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Blázquez A, Miguel-Escalada I, Portas-Gómez L, et al. Prolonged vaginal progesterone supplementation does not improve outcomes for Day 6 frozen blastocyst transfers in oocyte donation cycles. Hum Reprod. 2026. PMID: 41206359. doi:10.1093/humrep/deaf205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。